Liani Aquino Robles, MD
General Practice · San Sebastian, PRNPI 1538295431
Payments from drug & device makers
Across 165 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$486
- Amarin Pharma, Inc.$356
- Novo Nordisk$336
- AstraZeneca$252
- GSK$166
- Boehringer Ingelheim$163
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,886100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 32 | $486 |
| Amarin Pharma, Inc. | 21 | $356 |
| Novo Nordisk | 17 | $336 |
| AstraZeneca | 16 | $252 |
| GSK | 11 | $166 |
| Boehringer Ingelheim | 7 | $163 |
| Sanofi-aventis U.S. LLC | 9 | $147 |
| Johnson & Johnson | 9 | $146 |
| Abbott | 6 | $115 |
| Pfizer | 7 | $113 |
| AbbVie | 4 | $88 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $75 |
| Amgen | 3 | $69 |
| Novartis | 4 | $67 |
| Exact Sciences | 2 | $60 |
| Mylan Specialty L.p. | 3 | $47 |
| Insulet Corporation | 1 | $30 |
| Xeris Pharmaceuticals, Inc. | 1 | $28 |
| Edwards Lifesciences | 1 | $22 |
| Tactile Systems Technology Inc | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Bayer | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Merck | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$2,886 in reported general payments places this provider in the 95th percentile of 3,586 general practice providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 173 | $171,441 |
| JardianceEmpagliflozin | 132 | $142,752 |
| EliquisApixaban | 120 | $107,910 |
| Kesimpta PenOfatumumab | 11 | $94,170 |
| Humira(Cf) PenAdalimumab | 11 | $92,763 |
| FarxigaDapagliflozin Propanediol | 74 | $62,704 |
| LinzessLinaclotide | 78 | $60,411 |
| MounjaroTirzepatide | 47 | $54,408 |
| JanuviaSitagliptin Phosphate | 41 | $52,341 |
| DescovyEmtricitabine/Tenofov Alafenam | 18 | $38,651 |
| EntrestoSacubitril/Valsartan | 21 | $33,173 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $30,058 |
| XareltoRivaroxaban | 23 | $26,233 |
| MyrbetriqMirabegron | 40 | $25,899 |
| RestasisCyclosporine | 24 | $24,092 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $336 | $171,441173 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $163 | $162,416158 claims |
| PfizerEliquis | $113 | $107,910120 claims |
| AbbVieLinzess, Restasis, Synthroid | $88 | $88,159147 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $486 | $79,85191 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $252 | $78,18691 claims |
| MerckJanuvia, Isentress | $13 | $73,95152 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $166 | $44,29758 claims |
| NovartisEntresto | $67 | $33,17321 claims |
| Johnson & JohnsonXarelto | $146 | $26,23323 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $147 | $9,25813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,586 general practice providers in Puerto Rico.
Other general practice in San Sebastian
- Gregorio Cortes-MaisonetSan Juan$12.8M
- Barbara Orozco PerezCanovanas$5.1M
- Jesus Rodriguez RodriguezPonce$4.9M
- Luis PaganDorado$3.3M
- Cindy MartinezHormigueros$3.2M
- Gustavo AlbizuMorovis$3.1M
- Elham GhorbaniDorado$1.2M
- Victor MorenoMaunabo$903K
- Grisselle Ortiz RiveraMorovis$715K
- Elba PerezTrujillo Alto$651K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.